Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 (IMAGE)
Caption
Insilico is expected to record a revenue in the range of approximately USD102.5 million to approximately USD106.5 million for the First Half of 2026, representing a year-on-year increase of approximately 272.7% to 287.3%. Net profit is expected to be in the range of approximately USD33.5 million to approximately USD39.5 million for the First Half of 2026, while adjusted non-IFRS net profit in the range of approximately USD45.5 million to approximately USD51.5 million for the First Half of 2026.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content